About Atopic Dermatitis Treatment
Atopic dermatitis, also known as eczema, is a common allergic skin disease that makes skin red and itchy usually starts in early childhood. This skin disease can be associated with infection of bacteria, fungi, yeast and viruses. This condition is common in children but can occur at any age. Half of the patients suffering from moderate to severe atopic dermatitis also suffer from asthma, hay fever (allergic rhinitis), and food allergies. No cure has been found for this condition, but treatment and self-care measures can relieve itching and prevent new outbreaks.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Atopic Dermatitis Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Sanofi S.A. (France), Allergan, Inc. (Ireland), Novartis International AG (Switzerland), Bristol Myers Squibb (United States), Bayer AG (Germany), Meda Pharmaceuticals (Sweden), Anacor Pharmaceutical (United States), Pfizer Inc. (United States), Astellas Pharma Inc. (Japan) and Regeneron Pharmaceuticals, Inc. (United States) are some of the key players that are part of study coverage.
Segmentation Overview
AMA Research has segmented the market of Global Atopic Dermatitis Treatment market by and Region.
On the basis of geography, the market of Atopic Dermatitis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Atopic Dermatitis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment, the sub-segment i.e. Medications will boost the Atopic Dermatitis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Atopic Dermatitis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Corticosteroids will boost the Atopic Dermatitis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Increased Research and Development Activities and Improving Healthcare Facilities
Market Growth Drivers:
Rising Awareness among People about Treatment Options available for Atopic Dermatitis and Increasing Prevalence of Atopic Dermatitis among Children
Challenges:
Stringent Government Rules and Regulations
Restraints:
High Cost of Therapeutics
Opportunities:
Growth in the Healthcare Industry Worldwide and Increasing Government Fundings for Affordable Treatments
Market Leaders and their expansionary development strategies
On October 26, 2023, Regeneron and Sanofi announced a collaboration to develop and commercialize REGN4210, a novel investigational interleukin-23 (IL-23) receptor antibody, for the treatment of various inflammatory diseases, including moderate-to-severe atopic dermatitis.
On September 19, 2023, LEO Pharma and Almirall entered into a strategic partnership to co-commercialize LEO Pharma's JAK1 inhibitor, LEO 10367, for the treatment of atopic dermatitis and other immune-mediated diseases.
Key Target Audience
Atopic Dermatitis Treatment Providers, Emerging Companies, Research Professionals, Distributors and End-users
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.